Livforsakringsbolaget Skandia Omsesidigt trimmed its position in shares of Boston Scientific Corporation (NYSE:BSX) by 19.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,847 shares of the medical equipment provider’s stock after selling 5,100 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Boston Scientific were worth $517,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently modified their holdings of the company. Valeo Financial Advisors LLC acquired a new position in Boston Scientific in the third quarter valued at approximately $138,000. Steward Partners Investment Advisory LLC acquired a new position in Boston Scientific in the third quarter valued at approximately $139,000. San Francisco Sentry Investment Group CA acquired a new position in Boston Scientific in the second quarter valued at approximately $191,000. Ironwood Investment Counsel LLC acquired a new stake in Boston Scientific in the third quarter worth $204,000. Finally, Perkins Capital Management Inc. acquired a new stake in Boston Scientific in the third quarter worth $204,000. 89.84% of the stock is currently owned by hedge funds and other institutional investors.
In related news, SVP David A. Pierce sold 5,152 shares of Boston Scientific stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $27.00, for a total transaction of $139,104.00. Following the sale, the senior vice president now directly owns 38,116 shares of the company’s stock, valued at approximately $1,029,132. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP David A. Pierce sold 8,763 shares of Boston Scientific stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $27.74, for a total transaction of $243,085.62. Following the sale, the senior vice president now directly owns 24,201 shares in the company, valued at $671,335.74. The disclosure for this sale can be found here. Insiders have sold a total of 177,032 shares of company stock worth $4,648,733 over the last ninety days. 0.74% of the stock is currently owned by insiders.
Shares of Boston Scientific Corporation (BSX) traded up $0.70 during trading on Wednesday, reaching $26.81. 8,048,659 shares of the company’s stock traded hands, compared to its average volume of 9,880,000. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. Boston Scientific Corporation has a twelve month low of $23.29 and a twelve month high of $29.93. The firm has a market cap of $36,820.00, a PE ratio of 383.00, a price-to-earnings-growth ratio of 1.90 and a beta of 0.81.
Boston Scientific (NYSE:BSX) last released its earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 EPS for the quarter, meeting the consensus estimate of $0.34. Boston Scientific had a net margin of 1.15% and a return on equity of 24.04%. The firm had revenue of $2.41 billion for the quarter, compared to analyst estimates of $2.39 billion. During the same period last year, the firm earned $0.30 EPS. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. equities analysts forecast that Boston Scientific Corporation will post 1.37 EPS for the current year.
BSX has been the topic of several analyst reports. TheStreet upgraded shares of Boston Scientific from a “c+” rating to a “b” rating in a report on Thursday, January 18th. Canaccord Genuity initiated coverage on shares of Boston Scientific in a research report on Tuesday, October 24th. They set a “buy” rating and a $36.00 price objective for the company. Zacks Investment Research raised shares of Boston Scientific from a “sell” rating to a “buy” rating and set a $33.00 price objective for the company in a research report on Friday, October 20th. BMO Capital Markets reaffirmed a “buy” rating and issued a $31.00 target price on shares of Boston Scientific in a research report on Wednesday, November 29th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Wednesday, November 29th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $31.00.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/14/livforsakringsbolaget-skandia-omsesidigt-sells-5100-shares-of-boston-scientific-corporation-bsx.html.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.